<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="cf3405b0-5d45-4bfc-bd77-dd330fe9f04f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CLOBAZAM ORAL SUSPENSION safely and effectively. See full prescribing information for CLOBAZAM ORAL SUSPENSION. <br/>
      <br/> CLOBAZAM oral suspension, CIV <br/> Initial U.S. Approval: 2011</title>
   <effectiveTime value="20250110"/>
   <setId root="6332e71c-3b37-422c-838c-8a2489ac6009"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="035886746" root="1.3.6.1.4.1.519.1"/>
            <name>Precision Dose, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="e03cf2fd-facc-4b46-94a4-fa37eb710ff9"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68094-074" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Clobazam</name>
                        <formCode code="C42994" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>clobazam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="69238-1535" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="2.5" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2MRO291B4U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Clobazam</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2MRO291B4U" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Clobazam</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6M3P64V0NC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM ALUMINUM SILICATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="TTV12P4NEE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>XANTHAN GUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="94255I6E2T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCRALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D65DG142WK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MALTITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43204" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="68094-074-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="50" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68094-074-58" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43184" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CASE"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250310"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210039" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250310"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIV"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73365" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BERRY" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="3dfd36ca-9f9b-481f-8476-1cca47edb9d3"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: RISKS FROM CONCOMITANT USE WllH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS</content>
               </title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">The use of benzodiazepines, including clobazam oral suspension, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing clobazam oral suspension and throughout treatment, assess each patient's risk for abuse, misuse, and addiction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">The continued use of benzodiazepines, including clobazam oral suspension, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clobazam oral suspension after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clobazam oral suspension or reduce the dosage <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIOS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">The use of benzodiazepines, including clobazam oral suspension, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing clobazam oral suspension and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (<linkHtml href="#S5.2">5.2</linkHtml>).</content>
                           </item>
                           <item>
                              <content styleCode="bold">Abrupt discontinuation or rapid dosage reduction of clobazam oral suspension after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clobazam oral suspension or reduce the dosage (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="39c192ce-7766-461a-8575-1101761a5805"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <list listType="unordered" styleCode="disc">
                                       <item>Warnings and Precautions (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                                    </list>
                                 </td>
                                 <td>1/2023</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="8df1e8a3-6bc5-4f53-bf34-3ffc50640571"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Clobazam oral suspension is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Clobazam oral suspension is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="6d83f19a-d88e-4f6d-8ae5-21c2e0cf0e30"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>For doses above 5 mg/day administer in two divided doses. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Patients ≤ 30 kg body weight: Initiate at 5 mg daily and titrate as tolerated up to 20 mg daily. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Patients &gt; 30 kg body weight: Initiate at 10 mg daily and titrate as tolerated up to 40 mg daily. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Dosage adjustment needed in following groups: 									<list listType="unordered" styleCode="circle">
                                 <item>Geriatric patients (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S8.5">8.5</linkHtml>)</item>
                                 <item>Known CYP2C19 poor metabolizers (<linkHtml href="#S2.5">2.5</linkHtml>)</item>
                                 <item>Mild or moderate hepatic impairment; no information for severe hepatic impairment (<linkHtml href="#S2.7">2.7</linkHtml>, <linkHtml href="#S8.8">8.8</linkHtml>)</item>
                              </list>
                           </item>
                           <item>Oral suspension: Can be taken with or without food. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="2118da5d-1b8d-4bb6-8acf-7714c64e6a05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosing Information</title>
                     <text>
                        <paragraph>A daily dose of clobazam oral suspension greater than 5 mg should be administered in divided doses twice daily; a 5 mg daily dose can be administered as a single dose. Dose patients according to body weight. Individualize dosing within each body weight group, based on clinical efficacy and tolerability. Each dose in Table 1 (e.g., 5 mg to 20 mg in ≤ 30 kg weight group) has been shown to be effective, although effectiveness increases with increasing dose <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content> Do not proceed with dose escalation more rapidly than weekly, because serum concentrations of clobazam and its active metabolite require 5 and 9 days, respectively, to reach steady-state.</paragraph>
                        <table width="85%">
                           <caption>Table 1: Recommended Total Daily Dosing by Weight Group</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">≤ 30 kg Body Weight</th>
                                 <th styleCode="Rrule">&gt; 30 kg Body Weight</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Starting Dose</td>
                                 <td styleCode="Rrule">5 mg</td>
                                 <td styleCode="Rrule">10 mg</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Starting Day 7</td>
                                 <td styleCode="Rrule">10 mg</td>
                                 <td styleCode="Rrule">20 mg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Starting Day 14</td>
                                 <td styleCode="Rrule">20 mg</td>
                                 <td styleCode="Rrule">40 mg</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="5423c14a-3f20-49de-8520-fa2b9dd727dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Discontinuation or Dosage Reduction of Clobazam oral suspension</title>
                     <text>
                        <paragraph>To reduce the risk of withdrawal reactions, increased seizure frequency, and status epilepticus, use a gradual taper to discontinue clobazam oral suspension or reduce the dosage. Taper by decreasing the total daily dose by 5 mg/day to 10 mg/day on a weekly basis until discontinued. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="e9ffe538-83a3-4392-904b-775f58c457ef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Important Administration Instructions</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="9009345a-ce35-49f4-bdc4-4a400b2cc5b7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clobazam Oral Suspension Oral Administration</content>
                              </paragraph>
                              <paragraph>Clobazam oral suspension can be taken with or without food <content styleCode="italics">[see  <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Shake clobazam oral suspension well before every administration.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="f222608f-0b5a-4f4c-b1a5-9a7210f1d092"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Adjustments in Geriatric Patients</title>
                     <text>
                        <paragraph>Plasma concentrations at any given dose are generally higher in the elderly: proceed slowly with dose escalation. The starting dose should be 5 mg/day for all elderly patients. Then titrate elderly patients according to weight, but to half the dose presented in Table 1, as tolerated. If necessary and based upon clinical response, an additional titration to the maximum dose (20 mg/day or 40 mg/day, depending on weight) may be started on day 21 <content styleCode="italics">[see <linkHtml href="#S8.5">Use In Specific Populations (8.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="3cc245e5-7851-40d0-8008-43117d402931"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Adjustments in CYP2C19 Poor Metabolizers</title>
                     <text>
                        <paragraph>In CYP2C19 poor metabolizers, levels of N-desmethylclobazam, clobazam's active metabolite, will be increased. Therefore, in patients known to be CYP2C19 poor metabolizers, the starting dose should be 5 mg/day and dose titration should proceed slowly according to weight, but to half the dose presented in Table 1, as tolerated. If necessary and based upon clinical response, an additional titration to the maximum dose (20 mg/day or 40 mg/day, depending on the weight group) may be started on day 21 <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="9aebbc42-6654-42c1-b3fb-e3cd2b9d89ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Patients with Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is required for patients with mild and moderate renal impairment. There is no experience with clobazam oral suspension in patients with severe renal impairment or end stage renal disease (ESRD). It is not known if clobazam or its active metabolite, N-desmethylclobazam, is dialyzable <content styleCode="italics">[see <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="eea30bc0-3165-45f3-85e0-e5454bf27e0b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Dosage Adjustments in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>Clobazam oral suspension is hepatically metabolized; however, there are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of clobazam oral suspension. For this reason, proceed slowly with dosing escalations. For patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), the starting dose should be 5 mg/day in both weight groups. Then titrate patients according to weight, but to half the dose presented in Table 1, as tolerated. If necessary and based upon clinical response, start an additional titration on day 21 to the maximum dose (20 mg/day or 40 mg/day, depending on the weight group). There is inadequate information about metabolism of clobazam oral suspension in patients with severe hepatic impairment. Therefore no dosing recommendation in those patients can be given <content styleCode="italics">[see <linkHtml href="#S8.8">Use in Specific Populations (8.8)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="6d2a220b-46da-4eb1-97d7-90bf28214c66"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Oral Suspension: 2.5 mg/mL for oral administration. An off-white suspension.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Oral Suspension: 2.5 mg/mL (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="efda9bfd-6f99-4bb5-947b-ba9f246c12b5"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Clobazam oral suspension is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included serious dermatological reactions <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of hypersensitivity to the drug or its ingredients. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="723472ae-b8d9-4a55-be4f-be22d2bee5f1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Somnolence or Sedation: Monitor for central nervous system (CNS) depression. Risk may be increased with concomitant use of other CNS depressants. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Serious Dermatological Reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis): Discontinue clobazam at first sign of rash unless the rash is clearly not drug-related. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>Neonatal Sedation and Withdrawal Syndrome: Clobazam use during pregnancy can result in neonatal sedation and/or neonatal withdrawal. (<linkHtml href="#S5.8">5.8</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="d16607e9-dee6-4612-88c2-69a6c7be327e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risks from Concomitant Use with Opioids</title>
                     <text>
                        <paragraph>Concomitant use of benzodiazepines, including clobazam, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of benzodiazepines and opioids for patients for whom alternative treatment options are inadequate.</paragraph>
                        <paragraph>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe clobazam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. Advise both patients and caregivers about the risks of respiratory depression and sedation when clobazam is used with opioids <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="9d4cd1fa-2b6a-4e2b-bc9c-b5696524378d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Abuse, Misuse, and Addiction</title>
                     <text>
                        <paragraph>The use of benzodiazepines, including clobazam, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death<content styleCode="italics">[see <linkHtml href="#S9.2">Drug Abuse and Dependence (9.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Before prescribing clobazam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of clobazam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of clobazam along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants). If a substance use disorder Is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="fcca8588-cf6c-4cf5-a979-e1c955b55e3b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Dependence and Withdrawal Reactions</title>
                     <text>
                        <paragraph>To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clobazam or reduce the dosage <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content> Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="a9ff1491-912e-4759-b231-d5611f294050"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Acute Withdrawal Reactions</content>
                              </paragraph>
                              <paragraph>The continued use of benzodiazepines, including clobazam, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of clobazam after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) <content styleCode="italics">[see <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c313ba26-a043-4d88-8910-a366f46027b0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Protracted Withdrawal Syndrome</content>
                              </paragraph>
                              <paragraph>In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months <content styleCode="italics">[see <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="e8f8ecd7-5cb2-45d0-ac7e-ce8b4ec5bac9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Potentiation of Sedation from Concomitant Use with Central Nervous System Depressants</title>
                     <text>
                        <paragraph>Since clobazam has a central nervous system (CNS) depressant effect, patients or their caregivers should be cautioned against simultaneous use with other CNS depressant drugs or alcohol, and cautioned that the effects of other CNS depressant drugs or alcohol may be potentiated <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="a11e14dd-8020-46d3-96cc-d1136fbb91cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Somnolence or Sedation</title>
                     <text>
                        <paragraph>Clobazam causes somnolence and sedation. In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related.</paragraph>
                        <paragraph>In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment. Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system depressants. Prescribers should caution patients against engaging in hazardous activities requiring mental alertness, such as operating dangerous machinery or motor vehicles, until the effect of clobazam is known.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="9658bd9a-8b52-4ec9-bebd-06be84eb5f49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Serious Dermatological Reactions</title>
                     <text>
                        <paragraph>Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with clobazam in both children and adults during the postmarketing period. Patients should be closely monitored for signs or symptoms of SJS/TEN, especially during the first 8 weeks of treatment initiation or when re-introducing therapy. Clobazam should be discontinued at the first sign of rash, unless the rash Is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered <content styleCode="italics">[see <linkHtml href="#S4">contraindications (4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="ef45b2af-eab2-4959-96b2-54174643b81a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Suicidal Behavior and Ideation</title>
                     <text>
                        <paragraph>Antiepileptic drugs (AEDs), including clobazam, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</paragraph>
                        <paragraph>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [Cl]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.</paragraph>
                        <paragraph>The Increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</paragraph>
                        <paragraph>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Table 2 shows absolute and relative risk by indication for all evaluated AEDs.</paragraph>
                        <table width="85%">
                           <caption>Table 2: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</caption>
                           <col width="8%" align="left" valign="middle"/>
                           <col width="23%" align="center" valign="middle"/>
                           <col width="23%" align="center" valign="middle"/>
                           <col width="23%" align="center" valign="middle"/>
                           <col width="23%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Indication</th>
                                 <th styleCode="Rrule">Placebo Patients with Events per 1,000 Patients</th>
                                 <th styleCode="Rrule">Drug Patients with Events per 1,000 Patients</th>
                                 <th styleCode="Rrule">Relative Risk:<br/>Incidence of Drug Events in Drug Patients/Incidence in Placebo Patients</th>
                                 <th styleCode="Rrule">Risk Difference:<br/>Additional Drug<br/>Patients with Events<br/>par 1,000 Patients</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Epilepsy</td>
                                 <td styleCode="Rrule">1.0</td>
                                 <td styleCode="Rrule">3.4</td>
                                 <td styleCode="Rrule">3.5</td>
                                 <td styleCode="Rrule">2.4</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Psychiatric</td>
                                 <td styleCode="Rrule">5.7</td>
                                 <td styleCode="Rrule">8.5</td>
                                 <td styleCode="Rrule">1.5</td>
                                 <td styleCode="Rrule">2.9</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Other</td>
                                 <td styleCode="Rrule">1.0</td>
                                 <td styleCode="Rrule">1.8</td>
                                 <td styleCode="Rrule">1.9</td>
                                 <td styleCode="Rrule">0.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Total</td>
                                 <td styleCode="Rrule">2.4</td>
                                 <td styleCode="Rrule">4.3</td>
                                 <td styleCode="Rrule">1.8</td>
                                 <td styleCode="Rrule">1.9</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.</paragraph>
                        <paragraph>Anyone considering prescribing clobazam or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an Increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</paragraph>
                        <paragraph>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="bb102e47-7709-460b-9e2d-564dbed2bf20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Neonatal Sedation and Withdrawal Syndrome</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Use of clobazam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying and feeding difficulties) in the neonate <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content> Monitor neonates exposed to clobazam during pregnancy or labor for signs of sedation and monitor neonates exposed to clobazam during pregnancy for signs of withdrawal; manage these neonates accordingly.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="c72b73b2-fc7a-490b-b0d3-29ab1f7ea0c1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Clinically significant adverse reactions that appear in other sections of the labeling include the following:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Risks from Concomitant Use with Opioids <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Abuse, Misuse, and Addiction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Dependence and Withdrawal Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Potentiation of Sedation from Concomitant Use with Central Nervous System Depressants <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Somnolence or Sedation <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Serious Dermatological Reactions <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Suicidal Behavior and Ideation <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Neonatal Sedation and Withdrawal Syndrome <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions that occurred at least 10% more frequently than placebo in any clobazam dose included constipation, somnolence or sedation, pyrexia, lethargy, and drooling. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Precision Dose, Inc. at 1-800-397-9228 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="112314d6-b1d4-433c-8955-1a71cbbd1f76"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>During its development for the adjunctive treatment of seizures associated with LGS, clobazam was administered to 333 healthy volunteers and 300 patients with a current or prior diagnosis of LGS, including 197 patients treated for 12 months or more. The conditions and duration of exposure varied greatly and included single- and multiple-dose clinical pharmacology studies in healthy volunteers and two double-blind studies in patients with LGS (Study 1 and 2) <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content> Only Study 1 included a placebo group, allowing comparison of adverse reaction rates on clobazam at several doses to placebo.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="829e0358-8cca-46ed-b13a-86d0aa7f33be"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)</content>
                              </paragraph>
                              <paragraph>The adverse reactions associated with clobazam treatment discontinuation in ≥ 1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a5292ce1-3708-4929-ba25-033a45bc0652"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Most common Adverse Reactions in an LGS Placebo Controlled Clinical Trial (Study 1)</content>
                              </paragraph>
                              <paragraph>Table 3 lists the adverse reactions that occurred in ≥ 5% of clobazam-treated patients (at any dose) and at a rate greater than placebo-treated patients, in the randomized, double-blind, placebo-controlled, parallel group clinical study of adjunctive AED therapy for 15 weeks (Study 1).</paragraph>
                              <table width="85%">
                                 <caption>Table 3: Adverse Reactions Reported for ≥ 5% of Patients and More Frequently than Placebo in Any Treatment Group</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <col width="10%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" rowspan="2"/>
                                       <th styleCode="Rrule" rowspan="2">Placebo<br/>N=59<br/>%</th>
                                       <th colspan="3" styleCode="Botrule Rrule">Clobazam Dose Level</th>
                                       <th styleCode="Rrule" rowspan="2">All Clobazam<br/> N=179<br/> %</th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Rrule">Low<footnote>Maximum daily dose of 5 mg for ≤ 30 kg body weight; 10 mg for &gt; 30 kg body weight</footnote>
                                          <br/>N=58<br/>%</th>
                                       <th styleCode="Rrule">Medium<footnote>Maximum daily dose of 10 mg for ≤ 30 kg body weight; 20 mg for &gt; 30 kg body weight</footnote>
                                          <br/>N=62<br/>%</th>
                                       <th styleCode="Rrule">High<footnote>Maximum daily dose of 20 mg for ≤ 30 kg body weight; 40 mg for &gt; 30 kg body weight</footnote>
                                          <br/>N=59<br/>%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Vomiting</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Constipation</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Dysphagia</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Pyrexia</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">17</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">13</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Irritability</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Fatigue</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Infections and Infestations</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Upper respiratory tract infection</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">12</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Pneumonia</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Urinary tract infection</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Bronchitis</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Decreased appetite</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Increased appetite</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Nervous System Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Somnolence or Sedation</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">17</td>
                                       <td styleCode="Rrule">27</td>
                                       <td styleCode="Rrule">32</td>
                                       <td styleCode="Rrule">26</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">    Somnolence</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">24</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">22</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">    Sedation</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">9</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Lethargy</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">15</td>
                                       <td styleCode="Rrule">10</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Drooling</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">13</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Ataxia</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">10</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Psychomotor hyperactivity</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Dysarthria</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Psychiatric Disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Aggression</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">  Insomnia</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="6" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Respiratory Disorders</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">  Cough</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="a8f65077-751d-4c8d-a521-2a40f34bde1f"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Post-marketing Experience</title>
                     <text>
                        <paragraph>These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood Disorders:</content> Anemia, eosinophilia, leukopenia, thrombocytopenia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye Disorders:</content> Diplopia, vision blurred</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content> Abdominal distention</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions:</content> Hypothermia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> Hepatic enzyme increased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal:</content> Muscle spasms</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders:</content> Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders:</content> Urinary retention</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory Disorders:</content> Aspiration, respiratory depression</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders:</content> Rash, urticaria, angioedema, and facial and lip edema</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="95cd76d1-79d2-4692-8996-a8584f7fc09a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Alcohol: Increases blood levels of clobazam by about 50%. (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                           <item>Drugs metabolized by CYP2D6: Lower doses of these drugs may be required when used concomitantly with clobazam. (<linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item>Strong or Moderate CYP2C19 Inhibitors: Dosage adjustment of clobazam may be necessary. (<linkHtml href="#S7.4">7.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="e6d7addb-9fb5-4e0c-a35c-d555f8260852"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Opioids</title>
                     <text>
                        <paragraph>The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA<sub>A</sub> sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids and follow patients closely for respiratory depression and sedation <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="38667e55-3314-4330-ae11-3527b09c5a03"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 CNS Depressants and Alcohol</title>
                     <text>
                        <paragraph>Concomitant use of clobazam with other CNS depressants may increase the risk of sedation and somnolence <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Alcohol, as a CNS depressant, will interact with clobazam in a similar way and also increases clobazam's maximum plasma exposure by approximately 50%. Therefore, caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol, and caution that the effects of other CNS depressant drugs or alcohol may be potentiated <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="35d323a5-c0c1-46f2-8dbe-62e00a6d9972"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Effect of Clobazam on other Drugs</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="a027f841-5111-4033-86a2-e416443773c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hormonal Contraceptives</content>
                              </paragraph>
                              <paragraph>Clobazam is a weak CYP3A4 inducer. As some hormonal contraceptives are metabolized by CYP3A4, their effectiveness may be diminished when given with clobazam. Additional non-hormonal forms of contraception are recommended when using clobazam <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0f3ca2a0-aa03-4d5c-9196-b0fc0320f374"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drugs Metabolized by CYP2D6</content>
                              </paragraph>
                              <paragraph>Clobazam inhibits CYP2D6. Dose adjustment of drugs metabolized by CYP2D6 may be necessary <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="394c81a0-51b9-4206-bec6-0bd6824049a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Effect of Other Drugs on Clobazam</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="8eb0fbf1-43e5-4b0d-a0f6-df8c2f847a42"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong and moderate inhibitors of CYP2C19</content>
                              </paragraph>
                              <paragraph>Strong and moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam. This may increase the risk of dose-related adverse reactions. Dosage adjustment of clobazam may be necessary when co-administered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate CYP2C19 inhibitors (e.g., omeprazole) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="a227ca8f-bf59-4b39-bcf5-9b042c084582"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy: Based on animal data, may cause fetal harm. (<linkHtml href="#S8.1">8.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="62e44283-7bee-42ee-a5fc-ee15c9d7961d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="35c8e02c-c269-418b-ba06-c43337d6928d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as clobazam, during pregnancy. Healthcare providers are encouraged to recommend that pregnant women taking clobazam enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334 or online at http://www.aedpregnancyregistry.org/.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="9a1c364e-74a4-47c8-8219-544758f54416"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk summary</content>
                              </paragraph>
                              <paragraph>Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>
                                 </content> and <content styleCode="italics">
                                    <linkHtml href="#CC">Clinical Considerations</linkHtml>].</content> Available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>).</content>
                              </paragraph>
                              <paragraph>Administration of clobazam to pregnant rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation resulted in developmental toxicity, including increased incidences of fetal malformations and mortality, at plasma exposures for clobazam and its major active metabolite, N-desmethylclobazam, below those expected at therapeutic doses in patients <content styleCode="italics">[see <linkHtml href="#AD">Animal Data</linkHtml>].</content> Data for other benzodiazepines suggest the possibility of long-term effects on neurobehavioral and immunological function in animals following prenatal exposure to benzodiazepines at clinically relevant doses. Clobazam should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Advise a pregnant woman and women of childbearing age of the potential risk to a fetus.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="7369718f-c961-4d1b-9709-e1880658503d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="e23ed55c-24d5-43d3-8ab6-23cf4098fd1c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation in neonates. Monitor neonates exposed to clobazam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to clobazam during pregnancy for signs of withdrawal. Manage these neonates accordingly <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="34b66103-6b09-40bc-a12c-768bddd894c7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="1a0eda2f-42b7-4d4a-9ddf-bb5ec1700aac"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco, and other medications, have not confirmed these findings.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section ID="AD">
                                 <id root="f5879e74-e12e-4310-ae5c-332e686a3413"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In a study in which clobazam (0, 150, 450, or 750 mg/kg/day) was orally administered to pregnant rats throughout the period of organogenesis, embryofetal mortality and incidences of fetal skeletal variations were increased at all doses. The low-effect dose for embryofetal developmental toxicity in rats (150 mg/kg/day) was associated with plasma exposures (AUC) for clobazam and its major active metabolite, N-desmethylclobazam, lower than those in humans at the maximum recommended human dose (MRHD) of 40 mg/day.</paragraph>
                                    <paragraph>Oral administration of clobazam (0, 10, 30, or 75 mg/kg/day) to pregnant rabbits throughout the period of organogenesis resulted in decreased fetal body weights, and increased incidences of fetal malformations (visceral and skeletal) at the mid and high doses, and an increase in embryofetal mortality at the high dose. Incidences of fetal variations were increased at all doses. The highest dose tested was associated with maternal toxicity (ataxia and decreased activity). The low-affect dose for embryofetal developmental toxicity in rabbits (10 mg/kg/day) was associated with plasma exposures for clobazam and N-desmethylclobazam lower than those in humans at the MRHD.</paragraph>
                                    <paragraph>Oral administration of clobazam (0, 50, 350, or 750 mg/kg/day) to rats throughout pregnancy and lactation resulted in increased embryofetal mortality at the high dose, decreased pup survival at the mid and high doses and alterations in offspring behavior (locomotor activity) at all doses. The low-effect dose for adverse effects on pre- and postnatal development in rats (50 mg/kg/day) was associated with plasma exposures for clobazam and N-desmethylclobazam lower than those in humans at the MRHD.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="313205f9-362d-4e37-b914-74eaac249956"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="b4cd960a-5f1d-44cf-9835-493453cf11c5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Clobazam is excreted in human milk <content styleCode="italics">(see <linkHtml href="#data2">Data</linkHtml>).</content> There are reports of sedation, poor feeding, and poor weight gain in infants exposed to benzodiazepines through breast milk. There are no data on the effects of clobazam on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clobazam and any potential adverse effects on the breastfed infant from clobazam or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="dc54e0ad-ddc9-49ad-9029-3385c2f5773d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Adverse reactions such as somnolence and difficulty feeding have been reported in infants during breastfeeding in postmarketing experience with clobazam. Infants exposed to clobazam through breast milk should be monitored for sedation, poor feeding, and poor weight gain.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data2">
                           <id root="51ac2e92-31a9-45c1-ac9f-24936a71c372"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Scientific literature on clobazam use during lactation is limited. After short-term administration, clobazam and N-desmethylclobazam are transferred into breast milk.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3a">
                     <id root="fbdf0474-7fb9-4283-8f73-2d37838817ff"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>Administration of clobazam to rats prior to and during mating and early gestation resulted in adverse effects on fertility and early embryonic development at plasma exposures for clobazam and its major active metabolite, N-desmethylclobazam, below those in humans at the MRHD <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="0f8b47ae-3615-4e31-ba1e-254ee8227743"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in patients less than 2 years of age have not been established.</paragraph>
                        <paragraph>In a study in which clobazam (0, 4, 36, or 120 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days 14 to 48), adverse effects on growth (decreased bone density and bone length) and behavior (altered motor activity and auditory startle response; learning deficit) were observed at the high dose. The effect on bone density, but not on behavior, was reversible when drug was discontinued. The no-effect level for juvenile toxicity (36 mg/kg/day) was associated with plasma exposures (AUG) to clobazam and its major active metabolite, N-desmethylclobazam, less than those expected at therapeutic doses in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="6370c7b4-45fa-4d45-9c3c-21f5c47b2126"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of clobazam did not include sufficient numbers of subjects aged 65 and over to detenmine whether they respond differently from younger subjects. However, elderly subjects appear to eliminate clobazam more slowly than younger subjects based on population pharmacokinetic analysis. For these reasons, the initial dose in elderly patients should be 5 mg/day. Patients should be titrated initially to 10 mg/day to 20 mg/day. Patients may be titrated further to a maximum daily dose of 40 mg if tolerated <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="293ab731-2d68-4027-ad35-63ffd9ec534d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 CYP2C19 Poor Metabolizers</title>
                     <text>
                        <paragraph>Concentrations of clobazam's active metabolite, N-desmethylclobazam, are higher in CYP2C19 poor metabolizers than in extensive metabolizers. For this reason, dosage modification is recommended <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="fb0aa737-a599-47a7-95f1-427685fe2e7a"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>The pharmacokinetics of clobazam were evaluated in patients with mild and moderate renal impairment. There were no significant differences in systemic exposure (AUC and C<sub>max</sub>) between patients with mild or moderate renal impairment and healthy subjects. No dose adjustment is required for patients with mild and moderate renal impairment. There is essentially no experience with clobazam in patients with severe renal impairment or ESRD. It is not known if clobazam or its active metabolite, N-desmethylclobazam, is dialyzable <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.8">
                     <id root="5d61acf3-901e-499a-a74b-1cab9f10f95d"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.8 Hepatic Impairment</title>
                     <text>
                        <paragraph>Clobazam is hepatically metabolized; however, there are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of clobazam. For this reason, dosage adjustment is recommended in patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9). There is inadequate information about metabolism of clobazam in patients with severe hepatic impairment <content styleCode="italics">[see <linkHtml href="#S2.7">Dosage and Administration (2.7)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="468c618d-ef41-47a8-8d09-ad2a2e7a1b49"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20240430"/>
               <component>
                  <section ID="S9.1">
                     <id root="ab47d3df-5b4d-44a7-bffc-21f54e652f84"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Clobazam oral suspension contains clobazam, a Schedule IV controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.2">
                     <id root="2f4f7169-ab2e-40df-a284-60eb1001668a"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Clobazam is a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction.</paragraph>
                        <paragraph>Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders<content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo.</paragraph>
                        <paragraph>The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol).</paragraph>
                        <paragraph>The World Health Organization epidemiology database contains reports of drug abuse, misuse, and overdoses associated with clobazam.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.3">
                     <id root="c509424e-e7a6-4986-b7ad-6d294c61ad98"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="62c2bd33-0257-4f26-8fcb-b42b72907334"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Physical Dependence</content>
                              </paragraph>
                              <paragraph>Clobazam may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages i.e., higher and/or more frequent doses) and those who have had longer durations of use <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content> In clinical trials, cases of dependency were reported following abrupt discontinuation of clobazam.</paragraph>
                              <paragraph>To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clobazam or reduce the dosage <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>
                                 </content> and <content styleCode="italics">
                                    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="42e1a86a-1dc2-49f2-b096-537e26cadccf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Acute Withdrawal Signs and Symptoms</content>
                                    </paragraph>
                                    <paragraph>Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="6e63b1f8-728c-4883-b350-2c3688678cc7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Protracted Withdrawal Syndrome</content>
                                    </paragraph>
                                    <paragraph>Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ec14ef3e-9fe4-422a-ad9f-aeae6401f92a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tolerance</content>
                              </paragraph>
                              <paragraph>Tolerance to clobazam may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of clobazam may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="e09c7364-1875-40b8-a972-91d1135cdff3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage of benzodiazepines is characterized by central nervous system depression ranging from drowsiness to coma. In mild to moderate cases, symptoms can include drowsiness, confusion, dysarthria, lethargy, hypnotic state, diminished reflexes, ataxia, and hypotonia. Rarely, paradoxical or disinhibitory reactions (including agitation, irritability, impulsivity, violent behavior, confusion, restlessness, excitement, and talkativeness) may occur. In severe overdosage cases, patients may develop respiratory depression and coma. Overdosage of benzodiazepines in combination with other CNS depressants (including alcohol and opioids) may be fatal <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content> Markedly abnormal (lowered or elevated) blood pressure, heart rate, or respiratory rate raise the concern that additional drugs and/or alcohol are involved in the overdosage.</paragraph>
                  <paragraph>In managing benzodiazepine overdosage, employ general supportive measures, including intravenous fluids and airway maintenance. Flumazenil, a specific benzodiazepine receptor antagonist indicated for the complete or partial reversal of the sedative effects of benzodiazepines in the management of benzodiazepine overdosage, can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long-term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil may be increased in patients with epilepsy. Flumazenil is contraindicated in patients who have received a benzodiazepine for control of a potentially life-threatening condition (e.g., status epilepticus). If the decision is made to use flumazenil, it should be used as an adjunct to, not as a substitute for, supportive management of benzodiazepine overdosage. See the flumazenil injection Prescribing Information.</paragraph>
                  <paragraph>Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="4bab755e-c147-4846-a33a-e22010d72a49"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <table width="85%">
                     <caption>Table 4: Description</caption>
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Established Name:</td>
                           <td styleCode="Rrule">Clobazam Oral Suspension</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Dosage Forms:</td>
                           <td styleCode="Rrule">Oral Suspension</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Route of Administration:</td>
                           <td styleCode="Rrule">Oral</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Established Pharmacologic Class of Drug:</td>
                           <td styleCode="Rrule">Benzodiazepine</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">Chemical Name:</td>
                           <td styleCode="Rrule">7-Chloro-1-methyl-5-phenyl-1 H-1,5 benzodiazepine- 2,4(<content styleCode="italics">3H,5H</content>)-dione</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">Structural Formula:</td>
                           <td styleCode="Rrule">
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Clobazam is a white or almost white, crystalline powder with a slightly bitter taste; is slightly soluble in water, sparingly soluble in ethanol, and freely soluble in methylene chloride. The melting range of clobazam is from 182°C to 185°C. The molecular formula is C<sub>16</sub>H<sub>13</sub>O<sub>2</sub>N<sub>2</sub>Cl and the molecular weight is 300.7.</paragraph>
                  <paragraph>Clobazam oral suspension is available for oral administration as an off-white suspension containing clobazam at a concentration of 2.5 mg/mL. Inactive ingredients include berry flavor, citric acid monohydrate, dibasic sodium phosphate dihydrate, magnesium aluminum silicate, maltitol solution, methylparaben, polysorbate 80, propylene glycol, propylparaben, purified water, simethicone emulsion, sucralose, xanthan gum.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="clobazam-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="f21b0f45-da83-44df-b1ad-2038b35f7c33"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240430"/>
               <component>
                  <section ID="S12.1">
                     <id root="8e6784a9-3c54-4432-bad0-86187e463c69"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>The exact mechanism of action far clobazam, a 1,5-benzadiazepine, is not fully understood but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA<sub>A</sub> receptor.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="2e82b0f9-a7e8-4a30-a71c-7c0dc15760be"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="dba40921-bfb3-4e50-9fc3-960c8c7b8e77"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on Electrocardiogram</content>
                              </paragraph>
                              <paragraph>The effect of clobazam 20 mg and 80 mg administered twice daily on OTc interval was evaluated in a randomized, evaluator-blinded, placebo-, and active-controlled (moxifloxacin 400 mg) parallel thorough QT study in 280 healthy subjects. In a study with demonstrated ability to detect small effects, the upper bound of the one-sided 95% confidence interval for the largest placebo-adjusted, baseline-corrected QTc based on the Fridericia correction method was below 10 ms, the threshold for regulatory concern. Thus, at a dose two times the maximum recommended dose, clobazam did not prolong the QTc interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="da68a260-d796-43b7-ae89-591bd5e47d13"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The peak plasma levels (C<sub>max</sub>) and the area under the curve (AUG) of clobazam are dose-proportional over the dose range of 10 mg to 80 mg following single- or multiple-dose administration of clobazam. Based on a population pharmacokinetic analysis, the pharmacokinetics of clobazam are linear from 5 mg/day to 160 mg/day. Clobazam is converted to N-desmethylclobazam which has about 1/5 the activity of clobazam. The estimated mean elimination half-lives (t<sub>½</sub>) of clobazam and N-desmethylclobazam were 36 to 42 hours and 71 to 82 hours, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="d79c06f9-9e03-4d96-b752-abee3fd4b3bc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Clobazam is rapidly and extensively absorbed following oral administration. The time to peak concentrations (T<sub>max</sub>) of clobazam tablets under fasted conditions ranged from 0.5 to 4 hours after single- or multiple-dose administrations. The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%. After single dose administration of the oral suspension under fasted conditions, the T<sub>max</sub> ranged from 0.5 to 2 hours. Based on exposure (C<sub>max</sub> and AUC) of clobazam, clobazam tablets and suspension were shown to have similar bioavailability under fasted conditions. The administration of clobazam tablets with food or when crushed in applesauce does not affect absorption. Although not studied, the oral bioavailability of the oral suspension is unlikely to be affected under fed conditions.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="44ecabbf-f0c8-451b-b824-2eb9627601d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Clobazam is lipophilic and distributes rapidly throughout the body. The apparent volume of distribution at steady-state was approximately 100 L. The <content styleCode="italics">in vitro</content> plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d52fd714-970e-44bc-aee0-435558bdefeb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism and Excretion</content>
                              </paragraph>
                              <paragraph>Clobazam is extensively metabolized in the liver, with approximately 2% of the dose recovered in urine and 1 % in feces as unchanged drug. The major metabolic pathway of clobazam involves N-demethylation, primarily by CYP3A4 and to a lesser extent by CYP2C19 and CYP2B6. N-desmethylclobazam, an active metabolite, is the major circulating metabolite in humans, and at therapeutic doses, plasma concentrations are 3 to 5 times higher than those of the parent compound. Based on animal and <content styleCode="italics">in vitro</content> receptor binding data, estimates of the relative potency of N-desmethylclobazam compared to parent compound range from 1/5 to equal potency. N-desmethylclobazam is extensively metabolized, mainly by CYP2C19. N-desmethylclobazam and its metabolites comprise ~94% of the total drug-related components in urine. Following a single oral dose of radiolabeled drug, approximately 11% of the dose was excreted in the feces and approximately 82% was excreted in the urine.</paragraph>
                              <paragraph>The polymorphic CYP2C19 is the major contributor to the metabolism of the pharmacologically active N-desmethylclobazam <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>].</content> In CYP2C19 poor metabolizers, levels of N-desmethylclobazam were 5-fold higher in plasma and 2- to 3-told higher in the urine than in CYP2C19 extensive metabolizers.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="71fa3213-745d-4a97-abce-17563ea06380"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pharmacokinetics in Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="9b814669-f566-4b84-ba1f-a9e27116c0ee"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Age</content>
                                    </paragraph>
                                    <paragraph>Population pharmacokinetic analyses showed that the clearance of clobazam is lower in elderly subjects compared to other age groups (ages 2 to 64). Dosing should be adjusted in the elderly <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="32f1b268-7f28-463c-b34d-fa67b6c3e38a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Sex</content>
                                    </paragraph>
                                    <paragraph>Population pharmacokinetic analyses showed no difference in the clearance of clobazam between women and men.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="a4809f33-2aa6-48be-bd1f-d643eddab08a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race</content>
                                    </paragraph>
                                    <paragraph>Population pharmacokinetic analyses including Caucasian (75%), African American (15%), and Asian (9%) subjects showed that there is no evidence of clinically significant effect of race on the clearance of clobazam.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="1fff5da4-a980-4980-b4dd-f240ea0a0d82"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>The effect of renal impairment on the pharmacokinetics of clobazam was evaluated in patients with mild (creatinine clearance [CL<sub>CR</sub>] &gt; 50 to 80 mL/min; N=6) and moderate (CL<sub>CR</sub>=30 to 50 mL/min; N=6) renal dysfunction, with matching healthy controls (N=6), following administration of multiple doses of clobazam 20 mg/day. There were insignificant changes in C<sub>max</sub> (3% to 24%) and AUC (≤ 13%) tor clobazam or N-desmethylclobazam in patients with mild or moderate renal impairment compared to patients with normal renal function. Patients with severe renal impairment or ESRD were not included in this study.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ca6c860c-3109-488c-96d3-1bb2c73791c9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>There are limited data to characterize the effect of hepatic impairment on the pharmacokinetics of clobazam. In a small study, the pharmacokinetics of a 20 mg single oral dose of clobazam in 9 patients with liver impairment were compared to healthy controls (N=6). The C<sub>max</sub> and the mean plasma clearance of clobazam, as well as the C<sub>max</sub> of N-desmethylclobazam, showed no significant change compared to the healthy controls. The AUC values of N-desmethylclobazam in these patients were not available. Adjust dosage in patients with hepatic impairment <content styleCode="italics">[see <linkHtml href="#S2.7">Dosage and Administration (2.7)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="691115bc-cbf0-477f-b4e5-ab89c9f8bb8a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                           <component>
                              <section>
                                 <id root="34be872b-2c1b-4353-abe4-39d99438d7ae"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics underline">In vitro studies:</content>
                                    </paragraph>
                                    <paragraph>Clobazam did not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGTIA4, UGT1A6, or UGT2B4 <content styleCode="italics">in vitro.</content> N-desmethylclobazam showed weak inhibition of CYP2C9, UGT1A4, UGT1A6 and UGT2B4.</paragraph>
                                    <paragraph>Clobazam and N-desmethylclobazam did not significantly increase CYP1A2 or CYP2C19 activities, but did induce CYP3A4 activity in a concentration-dependent manner. Clobazam and N-desmethylclobazam also increased UGT1A1 mRNA but at concentrations much higher than therapeutic levels. The potential tor clobazam or N-desmethylclobazam to induce CYP2B6 and CYP2C8 has not been evaluated.</paragraph>
                                    <paragraph>Clobazam and N-desmethylclobazam do not inhibit P-glycoprotein (P-gp), but are P-gp substrates.</paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="cc233d83-b364-43c0-b0f3-2f61e51ab43a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics underline">In vivo studies:</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20240430"/>
                                 <component>
                                    <section>
                                       <id root="32fdc902-7f73-4c05-8ad5-2fa3a117377c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Potential for Clobazam to Affect Other Drugs</content>
                                          </paragraph>
                                          <paragraph>The effect of repeated 40 mg once-daily doses of clobazam on the pharmacokinetic profiles of single-dose dextromethorphan (CYP2D6 substrate), midazolam (CYP3A4 substrate), caffeine (CYP1A2 substrate), and tolbutamide (CYP2C9 substrate), was studied when these probe substrates were given as a drug cocktail (N=l 8).</paragraph>
                                          <paragraph>Clobazam increased AUC and C<sub>max</sub> of dextromethorphan by 90% and 59%, respectively, reflecting its inhibition of CYP2D6 <content styleCode="italics">in vivo.</content> Drugs metabolized by CYP2D6 may require dose adjustment when used with clobazam.</paragraph>
                                          <paragraph>Clobazam decreased the ALIC and C<sub>max</sub> of midazolam by 27% and 24%, respectively, and increased the AUC and C<sub>max</sub> of the metabolite 1-hydroxymidazolam by 4-fold and 2-fold, respectively. This level of induction does not call for dosage adjustment of drugs that are primarily metabolized by CYP3A4 when used concomitantly with clobazam. Some hormonal contraceptives are metabolized by CYP3A4 and their effectiveness may be diminished when given with clobazam <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>].</content> Repeated clobazam doses had no effect on caffeine and tolbutamide.</paragraph>
                                          <paragraph>A population pharmacokinetic analysis indicated clobazam did not affect the exposure of valproic acid (a CYP2C9/2C19 substrate) or lamotrigine (a UGT substrate).</paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="9d12e0ed-3899-4b9f-ad3c-ddbdb37e2819"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Potential for Other Drugs to Affect Clobazam</content>
                                          </paragraph>
                                          <paragraph>Co-administration of ketoconazole (a strong CYP3A4 inhibitor) 400 mg once-daily for 5 days increased clobazam AUC by 54%, with an insignificant effect on clobazam C<sub>max</sub>. There was no significant change in AUG and C<sub>max</sub> of N-desmethylclobazam (N=18).</paragraph>
                                          <paragraph>Strong (e.g., fluconazole, fluvoxamine, ticlopidine) and moderate (e.g., omeprazole) inhibitors of CYP2C19 may result in up to a 5-fold increase in exposure to N-desmethylclobazam, the active metabolite of clobazam, based on extrapolation from pharmacogenomic data <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml>].</content> Dosage adjustment of clobazam may be necessary when co-administered with strong or moderate CYP2C19 inhibitors <content styleCode="italics">[see <linkHtml href="#S7.4">Drug Interactions (7.4)</linkHtml>].</content>
                                          </paragraph>
                                          <paragraph>The effects of concomitant antiepileptic drugs that are CYP3A4 inducers (phenobarbital, phenytoin, and carbamazepine), CYP2C19 inducers (valproic acid, phenobarbital, phenytoin, and carbamazepine), and CYP2C19 inhibitors (felbamate and oxcarbazepine) were evaluated using data from clinical trials. Results of population pharmacokinetic analysis show that these concomitant antiepileptic drugs did not significantly alter the pharmacokinetics of clobazam or N-desmethylclobazam at steady-state.</paragraph>
                                          <paragraph>Alcohol has been reported to increase the maximum plasma exposure of clobazam by approximately 50%. Alcohol may have additive CNS depressant effects when taken with clobazam <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>].</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20240430"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.5">
                     <id root="106abaa5-4209-4a81-a9c1-5cc6fc48a19f"/>
                     <code code="66106-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>The polymorphic CYP2C19 is the main enzyme that metabolizes the pharmacologically active N-desmethylclobazam. Compared to CYP2C19 extensive metabolizers, N-desmethylclobazam AUC and C<sub>max</sub> are approximately 3 to 5 times higher in poor metabolizern (e.g., subjects with *2/*2 genotype) and 2 times higher in intermediate metabolizers (e.g., subjects with *1/*2 genotype). The prevalence of CYP2C19 poor metabolism differs depending on racial/ethnic background. Dosage in patients who are known CYP2C19 poor metabolizers may need to be adjusted <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The systemic exposure of clobazam is similar for both CYP2C19 poor and extensive metabolizers.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="c6c9f80d-8bdc-4b65-8fa0-59107db5d31f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240430"/>
               <component>
                  <section ID="S13.1">
                     <id root="c8e94a8e-68e8-4e7c-b961-a25fccb398ac"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20240430"/>
                     <component>
                        <section>
                           <id root="1b55c6ce-4dde-4a38-93f9-6e20a21a4a7a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>In mice, oral administration of clobazam (O, 6, 12, or 24 mg/kg/day) for 2 years did not result in an increase in tumors. The highest dose tested was approximately 3 times the maximum recommended human dose (MRHD) of 40 mg/day, based on body surface area (mg/m<sup>2</sup>).</paragraph>
                              <paragraph>In rats, oral administration of clobazam for 2 years resulted in increases in tumors of the thyroid gland (follicular cell adenoma and carcinoma) and liver (hepatocellular adenoma) at the mid and high doses. The low dose, not associated with an increase in tumors, was associated with plasma exposures (AUC) for clobazam and its major active metabolite, N-desmethylclobazam, less than that in humans at the MRHD.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4c431a20-3b61-4f42-915b-e0d74f7ef360"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Clobazam and the major active metabolite, N-desmethylclobazam, were negative for genotoxicity, based on data from a battery of <content styleCode="italics">in vitro</content>  (bacteria reverse mutation, mammalian clastogenicity) and <content styleCode="italics">in vivo</content> (mouse micronucleus) assays.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="189809f6-63be-4411-bc4b-23a9a9d23507"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a fertility study in which clobazam (50,350, or 750 mg/kg/day, corresponding to 12, 84 and 181 times the oral Maximum Recommended Human Dose, MRHD, of 40 mg/day based on mg/m<sup>2</sup> body surface) was orally administered to male and female rats prior to and during mating and continuing in females to gestation day 6, increases in abnormal sperm and pre-implantation loss were observed at the highest dose tested. The no-effect level for fertility and ear1y embryonic development in rats was associated with plasma exposures (AUC) tor clobazam and its major active metabolite, N-desmethylclobazam, less than those in humans at the maximum recommended human dose of 40 mg/day.</paragraph>
                           </text>
                           <effectiveTime value="20240430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="8b284cf4-73ba-4f0c-8886-32f4da2d8640"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The effectiveness of clobazam for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome was established in two multicenter controlled studies (Study 1 and Study 2). Both studies were similar in terms of disease characteristics and concomitant AED treatments. The most common concomitant AED treatments at baseline included: valproate, lamotrigine, levetiracetam, and topiramate.</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <section>
                     <id root="bd5a5cce-713a-49b5-a29a-96a018f22175"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 1</content>
                        </paragraph>
                        <paragraph>Study 1 (N=238) was a randomized, double-blind, placebo-controlled study consisting of a 4-week baseline period followed by a 3-week titration period and 12-week maintenance period. Patients age 2 to 54 years with a current or prior diagnosis of LGS were stratified into 2 weight groups (12.5 kg to ≤ 30 kg or &gt; 30 kg) and then randomized to placebo or one of three target maintenance doses of clobazam according to Table 5.</paragraph>
                        <table width="85%">
                           <caption>Table 5: Study 1 Total Daily Dose</caption>
                           <col width="34%" align="left" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <col width="33%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">≤ 30 kg Body Weight</th>
                                 <th styleCode="Rrule">&gt; 30 kg Body Weight</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Low Dose</td>
                                 <td styleCode="Rrule">5 mg daily</td>
                                 <td styleCode="Rrule">10 mg daily</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Medium Dose</td>
                                 <td styleCode="Rrule">10 mg daily</td>
                                 <td styleCode="Rrule">20 mg daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">High Dose</td>
                                 <td styleCode="Rrule">20 mg daily</td>
                                 <td styleCode="Rrule">40 mg daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Doses above 5 mg/day were administered in two divided doses.</paragraph>
                        <paragraph>The primary efficacy measure was the percent reduction in the weekly frequency of drop seizures (atonic, tonic, or myoclonic), also known as drop attacks, from the 4-week baseline period to 12-week maintenance period.</paragraph>
                        <paragraph>The pre-dosing baseline mean weekly drop seizure frequency was 98, 100, 61, and 105 for the placebo, low-, medium-, and high-dose groups, respectively. Figure 1 presents the mean percent reduction in weekly drop seizures from this baseline. All dose groups of clobazam were statistically superior (p ≤ 0.05) to the placebo group. This effect appeared to be dose dependent.</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th>Figure 1: Mean Percent Reduction from Baseline in Weekly Drop Seizure Frequency (Study 1)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM2"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Figure 2 shows changes from baseline in weekly drop seizure frequency by category tor patients treated with clobazam and placebo in Study 1. Patients in whom the seizure frequency increased are shown at left as "worse." Patients in whom the seizure frequency decreased are shown in five categories.</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th>Figure 2: Drop Seizure Response by Category for Clobazam and Placebo (Study 1)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM3"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>There was no evidence that tolerance to the therapeutic effect of clobazam developed during the 3-month maintenance period.</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="clobazam-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="clobazam-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b9b958e1-df2c-4875-aeb1-a176d21ab82f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 2</content>
                        </paragraph>
                        <paragraph>Study 2 (N=68) was a randomized, double-blind comparison study of high- and low-dose clobazam, consisting of a 4-week baseline period followed by a 3-week titration period and 4-week maintenance period. Patients age 2 to 25 years with a current or prior diagnosis of LGS were stratified by weight, then randomized to either a low or high dose of clobazam, and then entered a 3-week titration period.</paragraph>
                        <paragraph>The primary efficacy measure was the percent reduction in the weekly frequency of drop seizures (atonic, tonic, or myoclonic), also known as drop attacks, from the 4-week baseline period to the 4-week maintenance period.</paragraph>
                        <paragraph>A statistically significantly greater reduction in seizure frequency was observed in the high-dose group compared to the low-dose group (median percent reduction of 93% vs 29%; p &lt; 0.05).</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="effaf7f0-e27c-4b75-aff7-d06271cf0e66"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Clobazam oral suspension, <content styleCode="bold">2.5 mg/mL,</content> is a berry flavored off-white liquid.<br/>Store clobazam oral suspension in an upright position. It is available as follows:</paragraph>
                  <paragraph>NDC 68094-066-58<br/>4 ml per unit dose syringe<br/>Fifty (50) syringes per shipper</paragraph>
                  <paragraph>NDC 68094-074-58<br/>4 ml per unit dose ENFit syringe<br/>Fifty (50) syringes per shipper</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <section>
                     <id root="deff02bc-ea05-41c2-abc5-0ad015ddbc6a"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store oral suspension at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="15431354-3ddc-432f-b0ae-5c057affa341"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</paragraph>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <section>
                     <id root="767627ef-34ca-4f47-ab81-2e458217afd5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risks from Concomitant Use with Opioids</content>
                        </paragraph>
                        <paragraph>Inform patients and caregivers that potentially fatal additive effects may occur if clobazam is used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="beb9bce6-c851-438e-8597-f1f073173a68"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Abuse Misuse and Addiction</content>
                        </paragraph>
                        <paragraph>Inform patients that the use of clobazam, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S9.2">Drug Abuse and Dependence (9.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="689214d5-945d-44f5-98ce-da38441780b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Withdrawal Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients or caregivers that abrupt withdrawal of AEDs may increase their risk of seizure. Inform patients that the continued use of clobazam may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of clobazam may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of clobazam may require a slow taper <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="11e8e80e-23b7-4c23-91c3-d038c62f547b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Somnolence or Sedation</content>
                        </paragraph>
                        <paragraph>Advise patients or caregivers to check with their healthcare provider before clobazam is taken with other CNS depressants such as other benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or alcohol <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4</linkHtml>, <linkHtml href="#S5.5">5.5)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>If applicable, caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that clobazam does not affect them adversely (e.g., impair judgment, thinking or motor skills).</paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="d886fdfb-195f-463f-a24c-a81fd3ddc0b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity</content>
                        </paragraph>
                        <paragraph>Inform patients or caregivers that clobazam is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2b0caa30-4f6e-4842-a257-dacdb32da6ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Interactions with Hormonal Contraceptives</content>
                        </paragraph>
                        <paragraph>Counsel women to also use non-hormonal methods of contraception when clobazam is used with hormonal contraceptives and to continue these alternative methods for 28 days after discontinuing clobazam to ensure contraceptive reliability <content styleCode="italics">[see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3d27172f-4671-42a5-8e54-2e5d54dd0071"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Dermatological Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients or caregivers that serious skin reactions have been reported in patients taking clobazam. Serious skin reactions, including SJS/TEN, may need to be treated in a hospital and may be life-threatening. If a skin reaction occurs while taking clobazam, patients or caregivers should consult with healthcare providers immediately <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="6fb33ba6-29ef-43ff-bb1a-750b31693466"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Suicidal Thinking and Behavior</content>
                        </paragraph>
                        <paragraph>Counsel patients, their caregivers, and their families that AEDs, including clobazam, may increase the risk of suicidal thoughts and behavior and advise them of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm. Patients should report behaviors of concern immediately to healthcare providers <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9f37a626-a45c-4ed0-af39-d39fb2caad81"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise pregnant females that the use of clobazam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in newborns <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>
                           </content> and <content styleCode="italics">
                              <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content> Instruct patients to notify their healthcare provider if they are pregnant.</paragraph>
                        <paragraph>Encourage patients to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant while taking clobazam. The registry is collecting information about the safety of antiepileptic drugs during pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b72de82a-15a7-43cd-a210-a675e7a97868"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Counsel patients that clobazam, the active ingredient in clobazam oral suspension, is excreted in breast milk. Instruct patients to notify their healthcare provider if they are breast feeding or intend to breast feed. Instruct breastfeeding patients who have been administered clobazam to observe their infants for sedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="8799877f-b596-407c-8bf8-15f4f9cda176"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Packaged by:<br/>
                     <content styleCode="bold">Precision Dose, Inc.</content>
                     <br/>South Beloit, IL 61080</paragraph>
                  <paragraph>For inquiries call Precision Dose, Inc. at 1-800-397-9228 or email druginfo@precisiondose.com</paragraph>
                  <paragraph>Ll1567 Rev. 04/24</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="9a599dfe-b9d1-4abf-bb34-fad263d0debe"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="2%" align="left" valign="top"/>
                     <col width="28%" align="left" valign="top"/>
                     <col width="70%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th colspan="3" align="center" styleCode="Lrule Rrule">MEDICATION GUIDE<br/>Clobazam (kloe' ba zam)<br/>Oral Suspension, CIV</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <paragraph ID="important">
                                 <content styleCode="bold">What is the most important information I should know about clobazam oral suspension?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Clobazam oral suspension is benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma, and death.</content> Get emergency help right away if any of the following happens:<list listType="unordered" styleCode="circle">
                                       <item>shallow or slowed breathing</item>
                                       <item>breathing stops (which may lead to the heart stopping)</item>
                                       <item>excessive sleepiness (sedation)</item>
                                    </list>
                                 </item>
                              </list>									Do not drive or operate heavy machinery until you know how taking clobazam oral suspension with opioids affects you. 									<list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Risk of abuse, misuse, and addiction. There is a risk of abuse, misuse, and addiction with benzodiazepines, including clobazam oral suspension, which can lead to overdose and serious side effects including coma and death.</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including clobazam oral suspension.</content> These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects.</content>
                                       </item>
                                       <item>
                                          <content styleCode="bold">You can develop an addiction even if you take clobazam oral suspension as prescribed by your healthcare provider.</content>
                                       </item>
                                       <item>
                                          <content styleCode="bold">Take clobazam oral suspension exactly as your healthcare provider prescribed.</content>
                                       </item>
                                       <item>Do not share your clobazam oral suspension with other people.</item>
                                       <item>Keep clobazam oral suspension in a safe place and away from children.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Physical dependence and withdrawal reactions.</content> Clobazam oral suspension can cause physical dependence and withdrawal reactions.</item>
                                 <item>
                                    <content styleCode="bold">Do not suddenly stop taking clobazam oral suspension.</content> Stopping clobazam oral suspension suddenly can cause serious and life-threatening side effects, including unusual movements, responses, or expressions, siezures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms.</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Some people who suddenly stop benzodiazepines have symptoms that can last for several weeks to more than 12 months,</content> including, anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, felling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears.</item>
                                       <item>Physical dependence is not the same as drug addiction. Your your healthcare provider can tell you more about the differences between physical dependence and drug addiction.</item>
                                       <item>Do not take more clobazam oral suspension than prescribed or take clobazam oral suspension for longer than prescribed.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Clobazam oral suspension can make you sleepy or dizzy and can slow your thinking and motor skills.</content>
                                    <list listType="unordered" styleCode="circle">
                                       <item>Do not drive, operate heavy machinery, or do other dangerous activities until you know how clobazam oral suspension affects you.</item>
                                       <item>Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking clobazam oral suspension without first talking to your healthcare provider. When taken with alcohol or drugs that cause sleepiness or dizziness, clobazam oral suspension may make your sleepiness or dizziness much worse.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Serious skin reactions have been seen when clobazam oral suspension is taken with other medicines and may require stopping its use.</content> Do not stop taking clobazam oral suspension without first talking to your healthcare provider.<list listType="unordered" styleCode="circle">
                                       <item>A serious skin reaction can happen at any time during your treatment with clobazam oral suspension, but is more likely to happen within the first 8 weeks of treatment. These skin reactions may need to be treated right away.</item>
                                       <item>Call your healthcare provider immediately if you have skin blisters, rash, sores in the mouth, hives or any other allergic reaction.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Like other antiepileptic medicines, clobazam oral suspension may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Call your healthcare provider right away if you have any of these symptoms especially if they are new, worse, or worry you:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>thoughts about suicide or dying</item>
                                 <item>new or worse depression</item>
                                 <item>trouble sleeping (insomnia)</item>
                                 <item>acting on dangerous impulses</item>
                                 <item>attempts to commit suicide</item>
                                 <item>feeling agitated or restless</item>
                                 <item>new or worse anxiety or irritability</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>an extreme increase in activity and talking (mania)</item>
                                 <item>new or worse panic attacks</item>
                                 <item>acting aggressive, being angry or violent</item>
                                 <item>other unusual changes in behavior or mood</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How can I watch for early symptoms of suicidal thoughts and actions?</content>
                              <list listType="unordered" styleCode="circle">
                                 <item>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</item>
                                 <item>Keep all follow-up visits with your healthcare provider as scheduled.</item>
                              </list>									Call your healthcare provider between visits as needed, especially if you are worried about symptoms.<br/>Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).<br/>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is clobazam oral suspension?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Clobazam oral suspension is a prescription medicine used along with other medicines to treat seizures associated with Lennox-Gastaut syndrone in people 2 years of age or older.</item>
                                 <item>
                                    <content styleCode="bold">Clobazam oral suspension is a federally controlled substance (C-IV) because it contains clobazam that can be abused or lead to dependence.</content> Keep clobazam oral suspension in a safe place to prevent misuse and abuse. Selling or giving away clobazam oral suspension may harm others, and is againts the law. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.</item>
                              </list>									It is not known if clobazam oral suspension is safe and effective in children less than 2 years old. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not take clobazam oral suspension if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>are allergic to clobazam or any of the ingredients in clobazam oral suspension. See the end of this Medication Guide for a complete list of ingredients in clobazam oral suspension.</item>
                              </list>
                              <content styleCode="bold">Before you take clobazam oral suspension, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have liver or kidney problems</item>
                                 <item>have lung problems (respiratory disease)</item>
                                 <item>have or have had depression, mood problems, or suicidal thoughts or behavior</item>
                                 <item>use birth control medicine. Clobazam oral suspension may cause your birth control medicine to be less effective. Talk to your healthcare provider about the best birth control method to use.</item>
                                 <item>are pregnant or plan to become pregnant. 										<list listType="unordered" styleCode="circle">
                                       <item>Taking clobazam oral suspension late in pregnancy may cause your baby to have symptoms of sedation (breathing problems, sluggishness, low muscle tone) and/or withdrawal symptoms 0itteriness, irritability, restlessness, shaking, excessive crying, feeding problems).</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you are pregnant while taking clobazam oral suspension.</item>
                                       <item>If you become pregnant while taking clobazam oral suspension, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can registerby calling 1-888-233-2334. For more information about the registry go to http://www.aedpregnancyregistry.org. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. Clobazam can pass into breast milk. 										<list listType="unordered" styleCode="circle">
                                       <item>Breastfeeding during treatment with clobazam oral suspension may cause your baby to have sleepiness, feeding problems and decreased weight gain.</item>
                                       <item>Talk to your healthcare provider about the best way to feed your baby if you take clobazam oral suspension.</item>
                                    </list>
                                 </item>
                              </list>
                              <content styleCode="bold">Tell healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking clobazam oral suspension with certain other medicines can cause side effects or affect how well clobazam oral suspension or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take clobazam oral suspension?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take clobazam oral suspension exactly as your healthcare provider tells you to take.</item>
                                 <item>Your healthcare provider will tell you how much clobazam oral suspension to take and when to take it.</item>
                                 <item>Clobazam oral suspension can be taken with or without food.</item>
                                 <item>
                                    <content styleCode="bold">Shake clobazam oral suspension right before you take each dose.</content>
                                 </item>
                                 <item>Your healthcare provider may change your dose if needed.</item>
                                 <item>Do not stop taking clobazam oral suspension without first talking to your healthcare provider.</item>
                                 <item>Stopping clobazam oral suspension suddenly can cause serious problems.</item>
                                 <item>If you take too much clobazam oral suspension, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I avoid while taking clobazam oral suspension?</content>
                              <br/>See <content styleCode="bold">"<linkHtml href="#important">What is the most important information I should know about clobazam oral suspension?</linkHtml>"</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of clobazam oral suspension?<br/>Clobazam oral suspension may cause serious side effects, including:<br/>See "<linkHtml href="#important">What is the most important information I should know about clobazam oral suspension?</linkHtml>"<br/>The most common side effects of clobazam oral suspension include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="disc">
                                 <item>sleepiness</item>
                                 <item>cough</item>
                                 <item>acting aggressive, being angry or violent</item>
                                 <item>tiredness</item>
                                 <item>drooling</item>
                                 <item>pain with urination</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>difficulty sleeping</item>
                                 <item>problems with breathing</item>
                                 <item>constipation</item>
                                 <item>fever</item>
                                 <item>slurred speech</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">These are not all the possible side effects of clobazam oral suspension.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store clobazam oral suspension?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store clobazam oral suspension at room temperature between 68°F to 77°F (20°C to 25°C)</item>
                                 <item>
                                    <content styleCode="bold">Keep clobazam oral suspension and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of clobazam oral suspension.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not use clobazam oral suspension for a condition for which it was not prescribed. Do not give clobazam oral suspension to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about clobazam oral suspension that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in clobazam oral suspension?</content>
                              <br/>
                              <content styleCode="underline">Oral Suspension</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> clobazam<br/>
                              <content styleCode="bold">Inactive ingredients:</content> berry flavor, citric acid monohydrate, dibasic sodium phosphate dihydrate, magnesium aluminum silicate, maltitol solution, methylparaben, polysorbate 80, propylene glycol, propylparaben, purified water, simethicone emulsion, sucralose, xanthan gum.<br/>Package by:<br/>
                              <content styleCode="bold">Precision Dose, Inc.</content>
                              <br/>South Beloit, IL 61080<br/>For inquiries call Precision Dose, Inc. at 1-800-397-9228 or email druginfo@precisiondose.com</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Ll1567 Rev. 04/24</paragraph>
               </text>
               <effectiveTime value="20240430"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d4ec793e-94f8-4c75-8179-667d80dd5a80"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 4 mL Syringe Label</title>
               <text>
                  <paragraph>cloBAZam Oral Suspension CIV</paragraph>
                  <paragraph>10 mg/4 mL Delivers 4 mL</paragraph>
                  <paragraph>Each mL Contains: clobazam 2.5 mg</paragraph>
                  <paragraph>Shake syringe well before each use.</paragraph>
                  <paragraph>Store at 20-25° (68-77°F)</paragraph>
                  <paragraph>FOR ORAL ADMINISTRATION ONLY.</paragraph>
                  <paragraph>Pkg: Precision Dose, Inc. S. Beloit, IL 61080</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20240430"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 4 mL Syringe Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="clobazam-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>